POSTN and Hepatic steatosis: In agreement, both administration of a Periostin-neutralizing antibody and genetic ablation of Periostin largely attenuated DEX-induced hepatic steatosis, hyperglycemia and insulin resistance, indicating that Periostin plays an important role in the GCs-induced metabolic side effects.